NATCO Pharma Limited has announced the successful completion of the delisting of Adcock Ingram Holdings Limited, one of South Africa's oldest pharmaceutical companies, from the Johannesburg Stock Exchange (JSE) as of November 11, 2025. This landmark event marks the culmination of a strategic acquisition in which NATCO Pharma has acquired 35.75% of Adcock Ingram in a transaction valued at approximately US$ 226 million (ZAR 4 billion).

With roots tracing back to 1891, Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex. The company has shaped the pharmaceutical landscape in the region for 135 years.

In July 2025, NATCO Pharma offered ZAR 75 (US$ 4.36) per share to acquire Adcock Ingram's minority shareholders, a proposal that was approved in October 2025 with thumping support from the shareholders. With the completion of this acquisition of stake, NATCO Pharma attains market presence in South Africa.

The acquisition of stake is expected to create new opportunities for growth and innovation within the region. NATCO Pharma aims to leverage Adcock Ingram's established market position and consumer trust and expand its product offerings further in South Africa and beyond.

Rajeev Nannapaneni, CEO, NATCO Pharma stated, "This acquisition represents a significant step in our strategic growth plan across the globe. We are committed to preserving the rich legacy of Adcock Ingram while enhancing its capabilities to better serve the healthcare needs of communities across Africa and beyond."